Лучшие больницы для «Cervical Cancer Treatment» в Дели (NCR), Индия

Cervical cancer arises predominantly from the squamocolumnar junction of the uterine cervix, with over 90% of cases attributable to persistent high-risk Human Papillomavirus (HPV) infection—most commonly HPV genotypes 16 and 18. The two principal histological subtypes are squamous cell carcinoma (~70–75%) and adenocarcinoma (~20–25%), each carrying distinct prognostic implications. Precancerous lesions (CIN I–III / HSIL) detected through colposcopy and biopsy represent the earliest intervention window; invasive disease is staged using the FIGO 2018 classification system, which incorporates imaging findings from MRI, PET-CT, and lymph node assessment to guide treatment decisions.

• ELIGIBLE PATIENTS:
• Women diagnosed with cervical cancer at any FIGO stage (IA1 through IVA/IVB) seeking curative or palliative treatment
• Patients with confirmed HPV-related squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
• Women with recurrent or refractory cervical cancer following prior treatment, seeking second-line systemic therapy or palliative options
• Patients seeking fertility-preserving surgery (radical trachelectomy) for Stage IA2–IB1 disease with tumour ≤2 cm and no lymph node involvement
• +20 more

Surgical APPROACHES:

1. Radical Hysterectomy (Type B/C Querleu-Morrow / Wertheim Procedure): The gold-standard surgical intervention for Stage IA2–IB2 and select IIA1 cervical cancer. Involves en-bloc removal of the uterus, cervix, upper vaginal cuff (1–2 cm), parametrial tissue, and pelvic lymph node dissection (obturator, internal/external iliac, common iliac). Nerve-sparing variants (Type C1) preserve the inferior hypogastric plexus, significantly reducing bladder and bowel dysfunction compared to the classical non-nerve-sparing (Type C2) approach.

2. Minimally Invasive Radical Hysterectomy (Robotic / Laparoscopic): Robotic-assisted radical hysterectomy using the da Vinci Xi Surgical System offers a 3D operative field, 7-degrees-of-freedom instrument articulation, and magnified visualisation. However, following the LACC Trial (2018), open abdominal radical hysterectomy (OAR) remains the preferred approach for invasive disease due to superior disease-free and overall survival data. Robotic/laparoscopic approaches may be reserved for highly selected cases or clinical trials. Leading centres in India and the UAE adhere strictly to this evidence-based guideline.

3. Radical Trachelectomy (Fertility-Sparing): For Stage IA2–IB1 disease (tumour ≤2 cm, no lymph node involvement), radical trachelectomy with pelvic lymph node dissection preserves the uterine body and ovarian function, enabling future pregnancy. Available in both abdominal and vaginal (Dargent) approaches. Pregnancy rates post-trachelectomy range from 40–70% in published series.

PHASE 1 — PRE-ARRIVAL PLANNING (2–4 weeks before travel):

• GAF Healthcare case manager reviews existing biopsy reports, imaging, and medical records with the destination oncology team
• Multidisciplinary Tumour Board (MDT) review is scheduled; written treatment recommendation sent to the patient within 48–72 hours
• Pre-travel diagnostics checklist issued; any outstanding investigations (PET-CT, MRI) are either facilitated locally or arranged at the destination hospital
• e-Medical Visa (India) or UAE entry documentation assistance initiated; travel and accommodation for patient and one attendant arranged
• Anaesthesia pre-assessment questionnaire and cardiac clearance initiated if surgery is planned

PHASE 2 — ARRIVAL & INSTITUTIONAL WORKUP (Days 1–3):